A detailed history of Family Firm, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Family Firm, Inc. holds 4,967 shares of ABBV stock, worth $846,128. This represents 0.11% of its overall portfolio holdings.

Number of Shares
4,967
Previous 4,813 3.2%
Holding current value
$846,128
Previous $825,000 18.79%
% of portfolio
0.11%
Previous 0.09%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$163.84 - $199.33 $25,231 - $30,696
154 Added 3.2%
4,967 $980,000
Q2 2024

Jul 24, 2024

BUY
$154.79 - $180.76 $4,024 - $4,699
26 Added 0.54%
4,813 $825,000
Q1 2024

May 01, 2024

BUY
$159.82 - $182.1 $4,954 - $5,645
31 Added 0.65%
4,787 $871,000
Q4 2023

Feb 05, 2024

BUY
$137.6 - $154.97 $5,228 - $5,888
38 Added 0.81%
4,756 $737,000
Q3 2023

Oct 19, 2023

BUY
$133.59 - $154.65 $4,408 - $5,103
33 Added 0.7%
4,718 $703,000
Q2 2023

Aug 08, 2023

BUY
$132.51 - $164.9 $4,637 - $5,771
35 Added 0.75%
4,685 $631,000
Q1 2023

May 01, 2023

BUY
$144.61 - $166.54 $4,916 - $5,662
34 Added 0.74%
4,650 $741,000
Q4 2022

Feb 07, 2023

BUY
$138.31 - $165.87 $4,287 - $5,141
31 Added 0.68%
4,616 $746,000
Q3 2022

Nov 15, 2022

BUY
$134.21 - $153.93 $11,273 - $12,930
84 Added 1.87%
4,585 $615,000
Q2 2022

Dec 01, 2022

BUY
$137.62 - $174.96 $3,990 - $5,073
29 Added 0.63%
4,614 $707,000
Q1 2022

Nov 30, 2022

SELL
$131.98 - $163.75 $6,730 - $8,351
-51 Reduced 1.11%
4,534 $735,000
Q4 2021

Feb 02, 2022

BUY
$107.43 - $135.93 $3,330 - $4,213
31 Added 0.69%
4,501 $609,000
Q3 2021

Oct 22, 2021

BUY
$106.4 - $120.78 $3,192 - $3,623
30 Added 0.68%
4,470 $485,000
Q2 2021

Jul 21, 2021

BUY
$105.21 - $117.21 $3,051 - $3,399
29 Added 0.66%
4,440 $500,000
Q1 2021

May 06, 2021

BUY
$102.3 - $112.62 $3,375 - $3,716
33 Added 0.75%
4,411 $477,000
Q4 2020

Jan 20, 2021

BUY
$80.49 - $108.67 $16,741 - $22,603
208 Added 4.99%
4,378 $484,000
Q3 2020

Nov 04, 2020

SELL
$85.91 - $100.83 $12,886 - $15,124
-150 Reduced 3.47%
4,170 $365,000
Q2 2020

Aug 10, 2020

BUY
$73.37 - $98.18 $19,076 - $25,526
260 Added 6.4%
4,320 $424,000
Q1 2020

Apr 29, 2020

BUY
$64.5 - $97.79 $258 - $391
4 Added 0.1%
4,060 $309,000
Q4 2019

Feb 04, 2020

SELL
$72.13 - $90.25 $8,367 - $10,469
-116 Reduced 2.78%
4,056 $359,000
Q3 2019

Nov 12, 2019

BUY
$62.98 - $75.72 $314 - $378
5 Added 0.12%
4,172 $316,000
Q2 2019

Aug 06, 2019

BUY
$65.7 - $83.98 $197 - $251
3 Added 0.07%
4,167 $303,000
Q1 2019

May 06, 2019

BUY
$77.14 - $90.79 $308 - $363
4 Added 0.1%
4,164 $336,000
Q4 2018

Feb 05, 2019

BUY
$77.85 - $96.01 $6,850 - $8,448
88 Added 2.16%
4,160 $383,000
Q3 2018

Oct 31, 2018

SELL
$88.91 - $98.84 $37,253 - $41,413
-419 Reduced 9.33%
4,072 $385,000
Q2 2018

Aug 03, 2018

SELL
$89.78 - $106.23 $7,990 - $9,454
-89 Reduced 1.94%
4,491 $416,000
Q1 2018

Apr 26, 2018

SELL
$92.01 - $123.21 $7,820 - $10,472
-85 Reduced 1.82%
4,580 $433,000
Q4 2017

Feb 07, 2018

BUY
$89.56 - $98.21 $268 - $294
3 Added 0.06%
4,665 $451,000
Q3 2017

Nov 07, 2017

BUY
$69.85 - $89.22 $558 - $713
8 Added 0.17%
4,662 $414,000
Q2 2017

Aug 08, 2017

BUY
N/A
4,654
4,654 $337,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $301B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Family Firm, Inc. Portfolio

Follow Family Firm, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Family Firm, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Family Firm, Inc. with notifications on news.